EGFR and non-small cell lung carcinoma: Thomson et al.184 found that NSCLC cells with E-cadherin expression showed greater sensitivity to EGFR kinase inhibition (such as erlotinib), and cells overexpressed vimentin/fibronectin after EMT were insensitive to EGFR inhibition.